Technology
Health
Pharmaceutical

Evoke Pharma

$1.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.08 (-5.51%) Today
-$0.08 (-5.51%) Today

Why Robinhood?

You can buy or sell Evoke Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Evoke Pharma, Inc. Common Stock, also called Evoke Pharma, is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. Read More It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Employees
6
Headquarters
Solana Beach, California
Founded
2007
Market Cap
25.27M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
156.93K
High Today
$1.47
Low Today
$1.33
Open Price
$1.46
Volume
202.50K
52 Week High
$3.40
52 Week Low
$1.04

Collections

Technology
Health
Pharmaceutical
2013 IPO
US
North America

News

Simply Wall StMar 13

Could Evoke Pharma, Inc.’s (NASDAQ:EVOK) Investor Composition Influence The Stock Price?

If you want to know who really controls Evoke Pharma, Inc. (NASDAQ:EVOK), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, ‘Don’t tell me what you think, tell me what you have in your portfolio.’ Evoke Pharma is not a large company by global standards. It has a m...

1,322
Seeking AlphaMar 4

Evoke Pharma receives preliminary FDA communication on Gimoti NDA; shares down 51% premarket

Evoke Pharma (NASDAQ:EVOK) has received a multi-disciplinary review (DR) letter from the FDA in association with the Gimoti 505(b)(2) NDA. A DR letter is used to convey preliminary thoughts on deficiencies identified during the initial stage of NDA review. The letter described concerns in three sections: Chemistry; Clinical and Clinical Pharmacology not within the parameters for bioequivalence for abbreviated NDAs. The Company plans to respond to the deficiencies raised in the DR letter to allow time for...

2,038

Earnings

-$0.34
-$0.25
-$0.16
-$0.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 13, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.